This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Please select the most common characteristics of the patients with SCD you treat to learn more
Yes
No
12-18 years
>18 years
Not an actual patient.
Jamie
Relevant past medical history:
Current treatment of SCD:
Baseline lab workup:
Not an actual patient.
Maria
12-18 years
>18 years
Not an actual patient.
Gabriel
Not an actual patient.
Henry
Examine data from the HOPE and HOPE-KIDS 1 trials
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.
Oxbryta is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older.
This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).